Partnership Matters in Cancer Research
We’re collaborating with industry partners and looking at how investigational medication combinations could offer new potential for the treatment of different cancer types.
In some cases, cancer medications work better when more than one medication is given at a time. Using multiple medications that work in different ways may lessen the chance that cancer cells will become resistant to treatment. The stage and type of the cancer often determines whether single therapy or combination therapy is recommended.
These combination therapies provide opportunities that may help improve the lives of cancer patients.
Clinical Trial Diversity
At MSD, we believe in the importance of diversity. As we conduct our clinical trials, it’s our goal to have a representative mix of the population that will be using our therapeutic products. Differences in age, race, ethnicity, and sex can lead to different responses to medications and affect treatment outcomes.
Putting Diversity Into Practice
Lacking data from diverse populations may lead to overlooked differences in disease biology or impact patient safety. We’ve taken steps to close diversity gaps that might exist while conducting our clinical trials, including:
- Educating our staff on diversity issues with initiatives such as our Global Diversity and Inclusion Center of Excellence and various diversity educational programs
- Teaming up with clinical sites that include a diverse mix of investigators to grow programs that support the clinical trial education of minority Principal Investigators and patients
- Working with sites to make sure patient recruiting includes efforts to reach out to minorities
- Taking a closer look at enrollment data and making changes to bring in more diversity
- Bringing together a dedicated team of experts to help us promote diversity
- Creating tools for clinical sites that can improve health literacy among diverse communities
It is important that we prioritize diversity. That’s why we’ll continue to foster discussion, create awareness, and encourage and empower clinical sites to recruit patients based on disease prevalence in population groups that might otherwise be underrepresented in our clinical trials.